Vascular benefits of gliclazide beyond glycemic control

Metabolism: Clinical and Experimental

Volumn 49, Issue 10 SUPPL. 2, 2000, Pages 17-20

  Jennings, P E ^a  

^a YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLIBENCLAMIDE; GLICLAZIDE; METFORMIN;

ADULT; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETOGENESIS; DRUG EFFECT; ENDOTHELIUM; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0033787627     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2000.17825     Document Type: Conference Paper

References (33)

1. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Free radicals and disease in man
4. Lipid peroxidation in relation to prostacyclin and thromboxane physiology
5. Radicals in oxidative stress in diabetes
6. The potential role of oxidative stress in diabetes and its complications: Novel implications for theory and therapy
7. Increased diene conjugates in diabetic subjects with microangiopathy
8. The fluorescence of serum proteins in diabetes mellitus. Relationship to microangiopathy
9. Aldose reductase and complications of diabetes
10. The pathogenetic role of non-enzymatic glycosylation in diabetic complications
11. Vascular function in type 2 diabetes mellitus and pre-diabetes: The case for intrinsic endotheliopathy
12. Free radicals mediate endothelial cell dysfunction caused by elevated glucose
13. Risk factors for arterial disease in diabetes: Coagulopathy
14. Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulfonylurea (gliclazide)
15. Studies on fibrin network structure in human plasma. Part II - Clinical application: Diabetes and antidiabetic drugs
16. Platelet abnormalities in diabetes mellitus
17. Thromboxane biosynthesis and platelet function in type II diabetes mellitus
18. Gliclazide a free radical scavenger
19. Gliclazide scavenges hydroxyl, superoxide and nitric oxide radicals: An ESR study
20. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro
21. Gliclazide decreases cell-mediated low-density lipoprotein (LDL) oxidation and reduces monocyte adhesion to endothelial cells induced by oxidatively modified LDL
22. Normalization of plasma lipid peroxides, monocyte adhesion and tumour necrosis factor-alpha production in NIDDM patients after gliclazide treatment
23. Vascular action of gliclazide in diabetic rabbits
24. Effects of gliclazide on microvascular reactivity and permeability in diabetic hamsters
25. Highly glycosylated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels
26. Thromboxane/prostacyclin balance in type II diabetes: Gliclazide effects
27. Effect of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG and lipid peroxides in non-insulin dependent mellitus
28. Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment
29. In-vitro and in-vivo antioxidant properties of gliclazide
30. The effects of gliclazide on platelet function in patients with diabetes mellitus
31. Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes
32. Long-term comparison of oral hypoglycaemic agents in diabetic retinopathy